MZ1, a selective BRD4 degrader, has demonstrated superior efficacy in triple-negative breast cancer and leukemia models, suggesting a potential role in overcoming resistance to small-molecule BET inhibitors [150, 176, 177]. This evidence concerns the gene BRD4 and leukemia.